Correction to: Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.

Correction to: Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
J Dermatolog Treat. 2017 Mar 20;:1
Authors:
PMID: 28320215 [PubMed - as supplied by publisher]

Source: Journal of Dermatological Treatment - March 24, 2017 Category: Dermatology Tags: J Dermatolog Treat Source Type: research